Journal article
Telaprevir combination therapy in HCV/HIV co-infected patients (INSIGHT study): sustained virologic response at 12 weeks final analysis
Marisa Montes, Mark Nelson, Pierre Marie Girard, Joe Sasadeusz, Andrzej Horban, Beatriz Grinsztejn, Natalia Zakharova, Antonio Rivero, Erkki Lathouwers, Katrien Janssen, Sivi Ouwerkerk-Mahadevan, James Witek
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY | JOHN WILEY & SONS LTD | Published : 2014
Abstract
INTRODUCTION: We report the SVR12 final analysis of a phase 3 study of telaprevir in combination with peginterferon (P)/ribavirin (R) in HCV-genotype 1, treatment-naïve and -experienced patients with HCV/HIV co-infection (INSIGHT). MATERIALS AND METHODS: Patients receiving stable, suppressive HIV antiretroviral (ARV) therapy, containing atazanavir/ritonavir, efavirenz, darunavir/ritonavir, raltegravir, etravirine or rilpivirine, received telaprevir 750 mg q8h (1125 mg q8h if on efavirenz) plus P (180 µg once-weekly) and R (800 mg/day) for 12 weeks, followed by an additional 12 weeks (non-cirrhotic HCV treatment-naïve and relapse patients with extended rapid viral response [eRVR]) or 36 weeks..
View full abstract